An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.

Stopped This study was terminated early because the primary endpoint of PARAGON-HF was not met.

Conditions

• Heart Failure With Preserved Ejection Fraction (HFpEF)

Interventions

• DRUG: LCZ696

Sponsor

Novartis Pharmaceuticals